| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
NHI 2 manufacturers
- NHI-2
-
- $89.00
-
2026-07-13
- CAS:1269802-97-2
- Purity: 99.98%
- Supply Ability: 10g
|
| Product Name: | NHI 2 | | Synonyms: | NHI 2;Methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate;1H-Indole-2-carboxylic acid, 1-hydroxy-6-phenyl-4-(trifluoromethyl)-, methyl ester;NHI-2 >=98% (HPLC) | | CAS: | 1269802-97-2 | | MF: | C17H12F3NO3 | | MW: | 335.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1269802-97-2.mol |  |
| | NHI 2 Chemical Properties |
| Boiling point | 495.7±55.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | -20° | | solubility | Soluble in DMSO (up to 25 mg/ml). | | form | solid | | pka | 10+-.0.58(Predicted) | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. | | InChI | 1S/C17H12F3NO3/c1-24-16(22)15-9-12-13(17(18,19)20)7-11(8-14(12)21(15)23)10-5-3-2-4-6-10/h2-9,23H,1H3 | | InChIKey | YPPFWRWCZNXINO-UHFFFAOYSA-N | | SMILES | ON(C(C(OC)=O)=C1)C2=C1C(C(F)(F)F)=CC(C3=CC=CC=C3)=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | NHI 2 Usage And Synthesis |
| Description | NHI 2 is an inhibitor of lactate dehydrogenase A (LDHA; IC50 = 14.7 μM). It is selective for LDHA over LDHB (IC50 = 55.8 μM). It inhibits lactate production in HeLa cells when used at concentrations of 100 and 200 μM. NHI 2 is cytotoxic to HeLa cells (IC50 = 33.4 μM). | | Uses | NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 μM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 μM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S/G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppress tumor growth in mice[1][2]. | | in vivo | NHI-2 (0.9 mg/kg; Intra-tumoral; once daily for 15 days) can suppress tumor volume when combined with immune checkpoint inhibitors (ICIs) in murine B78 melanoma tumor model[2].
| Animal Model: | C57BL/6 female mice (6-8 weeks) were intradermally implanted with B78 syngeneic melanoma cells[2] | | Dosage: | 0.9 mg/kg | | Administration: | Intra-tumoral (IT) via percutaneous needle puncture; once daily for 15 days | | Result: | Suppressed tumor volume when combined with checkpoint inhibitors (ICIs). |
| | storage | Store at +4°C | | References | [1] GRANCHI C, CALVARESI E C, TUCCINARDI T, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds†[J]. Organic & Biomolecular Chemistry, 2013, 38: 6588-6596. DOI:10.1039/c3ob40870a
[2] M MAFTOUH. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia[J]. British Journal of Cancer, 2013, 110 1: 172-182. DOI:10.1038/bjc.2013.681
[3] CARLOTTA GRANCHI. Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells[J]. Journal of Medicinal Chemistry, 2011, 54 6: 1599-1612. DOI:10.1021/jm101007q
[4] S J ALLISON. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways[J]. Oncogenesis, 2014, 3 5: e102-e102. DOI:10.1038/oncsis.2014.16
[5] MICHAEL A LEA Charles D Yolanda Guzman. Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.[J]. Anticancer research, 2016, 36 4: 1479-1488. |
| | NHI 2 Preparation Products And Raw materials |
|